stoxline Quote Chart Rank Option Currency Glossary
Myovant Sciences Ltd. (MYOV)
26.98  -0.01 (-0.04%)    03-09 16:01
Open: 26.99
High: 27
Volume: 2,256,078
Pre. Close: 26.99
Low: 26.98
Market Cap: 2,624(M)
Technical analysis
2023-03-31 4:20:40 PM
Short term     
Mid term     
Targets 6-month :  31.6 1-year :  36.91
Resists First :  27.05 Second :  31.6
Pivot price 26.95
Supports First :  26.92 Second :  26.84
MAs MA(5) :  26.97 MA(20) :  26.95
MA(100) :  26.72 MA(250) :  19.2
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  84.2 D(3) :  69
RSI RSI(14): 61
52-week High :  27.05 Low :  7.67
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ MYOV ] has closed below upper band by 18.8%. Bollinger Bands are 94.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 80 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 27.04 - 27.18 27.18 - 27.29
Low: 26.66 - 26.81 26.81 - 26.93
Close: 26.77 - 26.99 26.99 - 27.18
Company Description

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Headline News

Fri, 10 Mar 2023
Sumitovant Biopharma Completes Acquisition of Myovant Sciences - PR Newswire

Thu, 26 Jan 2023
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 - Yahoo Finance

Tue, 29 Nov 2022
US FDA approves Pfizer-Myovant's Myfembree for endometriosis pain - Pharmaceutical Technology

Wed, 26 Oct 2022
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022 - GlobeNewswire

Sun, 23 Oct 2022
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement - PR Newswire

Sun, 02 Oct 2022
Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 97 (M)
Shares Float 51 (M)
Held by Insiders 48.6 (%)
Held by Institutions 56.2 (%)
Shares Short 8,390 (K)
Shares Short P.Month 6,740 (K)
Stock Financials
EPS -1.92
EPS Est Next Qtrly -0.44
EPS Est This Year -1.45
EPS Est Next Year -1.21
Book Value (p.s.) -5.75
Profit Margin -48.5 %
Operating Margin -38.8 %
Return on Assets (ttm) -18.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 84 %
Gross Profit (p.s.) 0.74
Sales Per Share 3.89
EBITDA (p.s.) -1.5
Qtrly Earnings Growth 0 %
Operating Cash Flow -270 (M)
Levered Free Cash Flow -149 (M)
Stock Valuations
PE Ratio -14.06
PEG Ratio 0
Price to Book value -4.7
Price to Sales 6.92
Price to Cash Flow -9.73
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android